Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma.

Alka Singh¹, Michael Korzinkin², Viktoria Sarkisova², Ekaterina Vergasova², Ari J Rosenberg¹, Karthik Suresh³, Vasudha Mishra¹, Yuxuan Miao⁴, Le Shen^5,6, Julia Smolik⁷, Alexander Veviorskiy⁷, Frank W Pun², Xiangying Cheng¹, Claudia Wing¹, Jayant Pinto⁵, Christopher M Low⁵, Mark W Lingen⁶, Lisa Rooper⁸, Alexander T Pearson¹, Everett E Vokes¹, Xuanyao Liu⁹, Nyall London¹⁰, Alex Zhavoronkov¹¹, Nishant Agrawal¹², Evgeny Izumchenko¹³

¹Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA.

²Insilico Medicine Hong Kong Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, China.

³Division of Pulmonary Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.

⁴Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA.

⁵Department of Surgery, University of Chicago, Chicago, IL, USA.

⁶Department of Pathology, University of Chicago, Chicago, IL, USA.

⁷Insilico Medicine AI Ltd., Abu Dhabi, UAE.

⁸Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

⁹Department of Human Genetics, University of Chicago, Chicago, IL, USA.

¹⁰Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.

¹¹Insilico Medicine Hong Kong Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong, China. alex@insilico.com.

¹²Department of Surgery, University of Chicago, Chicago, IL, USA. nishant.agrawal@uchicagomedicine.org.

¹³Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA. izumchen@uchicago.edu.

PubMed DOI

Abstract

Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy arising de novo or from inverted papilloma (IP), a benign neoplasm with malignant potential. The molecular drivers of IP-associated SNSCC (IP-SNSCC) remain poorly defined, and no effective therapies are available. Progress is hindered by limited preclinical studies and prospective clinical investigations. We performed multi-omic profil…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.